NCT07006727View on ClinicalTrials.gov

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 16, 2025

Primary Completion Date

June 17, 2031

Study Completion Date

June 17, 2031

Conditions
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate CancerGastroenteropancreatic Neuroendocrine Carcinoma
Interventions
DRUG

225Ac-ETN029

Radioligand therapy

DRUG

111In-ETN029

Radioligand imaging agent

Trial Locations (2)

52242

RECRUITING

University Of Iowa, Iowa City

H3T 1E2

RECRUITING

Novartis Investigative Site, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY